

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/212053 A2

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 21/00 (2006.01)

A61P 21/04 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/027801

(22) International Filing Date:

16 April 2021 (16.04.2021)

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/011,986 17 April 2020 (17.04.2020) US

63/038,633 12 June 2020 (12.06.2020) US

63/112,375 11 November 2020 (11.11.2020) US

(71) Applicants: **NEWYORK UNIVERSITY** [US/US]; 70 Washington Square South, New York, NY 10012 (US). **ARGENX IIP BV** [BE/BE]; Industriepark Zwijnaarde 7, 9052 Ghent (BE).

(72) Inventors: **BURDEN, Steven J.**; c/o New York University, 540 First Avenue, New York, NY 10016 (US). **KOIDE, Shohei**; c/o New York University, 522 First Avenue, New York, NY 10016 (US). **KOIDE, Akiko**; c/o New York University, 522 First Avenue, New York, NY 10016 (US). **LELOUP, Nadia**; c/o New York University, 522 First Avenue, New York, NY 10016 (US). **OURY, Julien**; 130 East 35th Street Apt 5B, New York, NY 10016 (US). **SILENCE, Karen**; Industriepark Zwijnaarde 7, 9052 Ghent (BE). **VANHAUWAERT, Roeland**; Industriepark Zwijnaarde 7, 9052 Ghent (BE). **BLANCHETOT, Christophe**; Industriepark Zwijnaarde 7, 9052 Ghent (BE).

(74) Agent: **STEGMANN, Tamara**; Nederlandsch Octrooibureau, P.O. Box 29720, 2505 LS The Hague (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: THERAPEUTIC MUSK ANTIBODIES

(57) Abstract: The present invention relates to antibody -based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.

WO 2021/212053 A2